| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GNg8 |
| Uniprot No | Q9UK08 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-67aa |
| 氨基酸序列 | MSNNMAKIAE ARKTVEQLKL EVNIDRMKVS QAAAELLAFC ETHAKDDPLV TPVPAAENPF RDKRLFC |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GNg8重组蛋白的虚构参考文献示例，供参考：
---
1. **标题**: *Expression and Functional Characterization of Recombinant GNG8 in Mammalian Cells*
**作者**: Zhang L et al.
**摘要**: 本研究成功构建了人源GNG8基因的重组表达载体，并在HEK293细胞中实现高效表达。通过亲和层析纯化获得高纯度蛋白，功能实验表明GNG8参与调节G蛋白偶联受体(GPCR)下游的cAMP信号通路。
2. **标题**: *Crystal Structure of GNG8 Reveals Key Interactions in Gβγ Dimer Formation*
**作者**: Patel R et al.
**摘要**: 通过X射线晶体学解析了重组GNG8蛋白与Gβ亚基的复合物结构，揭示了Gγ8特异性结合Gβ的分子机制，为靶向G蛋白信号通路的药物设计提供了结构基础。
3. **标题**: *GNG8 Recombinant Protein Modulates Neuronal Calcium Channels in vitro*
**作者**: Müller S et al.
**摘要**: 研究证明，重组GNG8蛋白可与神经元钙离子通道Cav2.2直接相互作用，调节其电生理活性，提示GNG8在神经信号传递及疾病治疗中的潜在作用。
4. **标题**: *Development of a GNG8-Specific Nanobody for GPCR Signaling Studies*
**作者**: Kim J et al.
**摘要**: 基于重组GNG8蛋白免疫筛选，获得高特异性纳米抗体，该工具可阻断Gβγ8复合物与下游效应分子的结合，为GPCR功能研究提供了新手段。
---
注：以上文献为模拟内容，实际研究中请通过学术数据库检索真实文献。
The GNg8 recombinant protein is a engineered biomolecule designed for applications in biomedical research, therapeutic development, and diagnostic tools. Derived from genetic recombination technology, it typically involves the fusion or modification of native protein domains to enhance stability, solubility, or functional specificity. The "GNg8" designation suggests a unique construct identifier, potentially linked to its target antigen or structural configuration. Such recombinant proteins are commonly produced in heterologous expression systems like *E. coli* or mammalian cell cultures, enabling scalable purification through affinity tags (e.g., His-tag, GST-tag).
This protein class often serves as a critical reagent in vaccine development, particularly for viral pathogens. For instance, GNg8 may mimic antigenic epitopes from infectious agents (e.g., SARS-CoV-2 spike protein domains) to stimulate immune responses or detect neutralizing antibodies. Its design might incorporate mutations to optimize receptor-binding affinity or evade immune recognition, balancing immunogenicity and safety. In therapeutic contexts, recombinant proteins like GNg8 are explored for targeted drug delivery, immunotherapy (e.g., checkpoint inhibitors), or as biosensors in diagnostic assays.
The development of GNg8 aligns with advances in structural biology and computational modeling, allowing precision engineering of functional domains. Quality control metrics emphasize >95% purity and validated bioactivity through ELISA, SPR, or cell-based assays. As a research tool, it facilitates mechanistic studies of protein-protein interactions and pathogen-host dynamics. Ongoing studies may focus on its stability under physiological conditions, batch-to-batch consistency, and preclinical efficacy in animal models. Such recombinant proteins represent a cornerstone of modern biologics, accelerating translational research in infectious diseases, oncology, and autoimmune disorders.
×
